Satraplatin in the treatment of hormone-refractory prostate cancer
- 1 November 2005
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 96 (7) , 990-994
- https://doi.org/10.1111/j.1464-410x.2005.05799.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate CancerOncology, 2005
- Second-Line Chemotherapy for Hormone-Refractory Prostate Cancer: Has the Time Come?Clinical Prostate Cancer, 2004
- Novel therapeutic strategies for androgen-independent prostate cancer: An updateSeminars in Oncology, 2004
- Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapyCancer Chemotherapy and Pharmacology, 2000
- Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.Japanese Journal of Clinical Oncology, 2000
- An update on satraplatin: the first orally available platinum anticancer drugExpert Opinion on Investigational Drugs, 2000
- Phase I study of oral JM216 given twice dailyCancer Chemotherapy and Pharmacology, 1998
- Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.Journal of Clinical Oncology, 1997
- Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor modelsCancer Chemotherapy and Pharmacology, 1997
- A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administrationCancer Chemotherapy and Pharmacology, 1995